Sleep apnea

Frage

Hello, could you provide some information about sleep apnea and cystic fibrosis? I'm currently at my fourth appointment in the sleep lab, and it seems I'll be starting nighttime mask ventilation to treat the breathing pauses during the night. Who else could I contact who has experience with this? What do I need to know about the mask ventilation device? Thank you.

Antwort

Hello,

Regarding your question about the connection between cystic fibrosis (CF) and obstructive sleep apnea (OSA), we would like to offer you a medical assessment.

In obstructive sleep apnea, breathing is repeatedly restricted or interrupted during sleep due to a relaxation and narrowing of the upper airways. The resulting pauses in breathing can lead to a drop in oxygen saturation and, depending on the severity, also to an increase in the carbon dioxide level in the blood. This leads to repeated brief awakenings, during which the airways reopen and breathing resumes. These awakenings are often not consciously perceived by those affected, but they can significantly disrupt sleep.

Obstructive sleep apnea can occur more frequently in people with cystic fibrosis than in the general population. For the assessment of cystic fibrosis (CF), it is particularly relevant that the effects of both conditions can exacerbate each other. Existing obstructive sleep apnea (OSA) can, in particular, intensify nighttime oxygen deprivation and, with impaired ventilation, also lead to additional CO₂ retention. This can further impair breathing, which is already compromised by CF. Furthermore, pronounced and untreated nighttime oxygen deprivation places an additional burden on the cardiovascular system.

However, OSA is not always immediately diagnosed in people with CF, as symptoms such as fatigue, exhaustion, or non-restorative sleep can also occur in the context of CF. Indications of OSA can include loud snoring, observed pauses in breathing, night sweats, restless sleep, and pronounced daytime sleepiness.

Therefore, if you have already undergone an examination in a sleep lab, this is an important and sensible step. The findings obtained there are crucial for determining the next steps. These include, among other things, the frequency and duration of breathing pauses, nighttime oxygen saturations, and—if measured—nighttime CO₂ levels. These parameters are of particular importance for choosing the appropriate therapy in cystic fibrosis (CF).

If you are diagnosed with obstructive sleep apnea (OSA) requiring treatment, therapy should always be tailored to your individual CF situation. The first priority is to ensure the best possible adjustment and optimization of your CF therapy. Depending on the findings, additional nighttime respiratory support may be necessary. CPAP or BiPAP/NIV therapy are particularly suitable options. If there is also a nighttime oxygen deficiency, supplemental oxygen may be required.

The appropriate form of respiratory support cannot be determined solely based on an OSA diagnosis, but rather depends on the individual findings. In cases of predominantly obstructive problems, CPAP therapy is often sufficient. If there is also a significant impairment of ventilation or a nocturnal increase in CO₂ levels, BiPAP/NIV therapy can be beneficial for people with cystic fibrosis (CF), as it actively supports ventilation in addition to keeping the airways open.

The setting of the appropriate ventilation pressure and the selection of the right mask should be determined individually in a sleep lab or by the treating pulmonology team. Especially with long-term therapy, it is important that the mask fits well and does not cause pressure sores, pain, or significant leaks. Good tolerability is crucial for the therapy to be used regularly and continuously, and thus be effective.

Due to cystic fibrosis, there are generally no fundamental special requirements for selecting the device itself. However, personal factors can certainly be taken into account. These include, for example, the noise level of the device, especially if you sleep in the same room as a partner, as well as the size and weight of the device if you travel frequently for work or other reasons and stay overnight away from home.

Since CPAP or BiPAP/NIV therapy is generally a long-term treatment, a gradual adjustment period is advisable. Especially when there is no acute respiratory emergency, sufficient time should be allowed to become accustomed to the mask and the nighttime breathing support. Should any problems arise with the mask, pressure settings, sleep quality, or tolerability, the therapy should not simply be discontinued, but rather discussed with the treating team and adjusted if necessary.

In summary, OSA in patients with cystic fibrosis should be taken seriously and treated if it is severe. The results of the sleep study, the nocturnal oxygen saturation, and, if measured, the CO₂ levels are particularly important for individual treatment decisions. Whether CPAP or BiPAP/NIV therapy is appropriate in your case should therefore be decided jointly with your pulmonology or sleep medicine team based on these findings.

We hope that this information clarifies the connections and possible further treatment steps and supports you in your future discussions with your doctors.

Sincerely,

Dr. Christina Smaczny

12.10.2026